Market Size, Demand & Growth

Compound management is not a manufacturing business; it is the laboratory backbone of drug discovery. A compound management operation acquires, weighs, dissolves, stores, reformats and distributes the chemical-compound libraries and biosamples that pharmaceutical and biotech screening teams test against disease targets. The product a bureau actually sells is not "storage" - it is sample integrity, chain-of-custody, and the ability to put an assay-ready plate on a scientist's bench within hours of a request.

The global compound management market sat at roughly $473.3 million in 2025 and is forecast to climb to $1.08 billion by 2031, a compound annual growth rate of about 14.87% (Mordor Intelligence, 2026). A separate estimate put the 2024 base at $487.9 million heading toward $1,721.3 million by 2033 at a 15.1% CAGR (Acumen Research and Consulting, 2025). The numbers differ by methodology, but every credible source agrees on the direction: double-digit growth driven by rising drug-discovery activity and a structural shift toward outsourcing.

That outsourcing shift is the opening for a new entrant. Products - automated stores, liquid handlers, software - hold the majority of spend at about 58.55% of the 2025 market, but the outsourcing-services segment is growing faster, at roughly a 16.25% CAGR, as pharma and biotech firms decide that running their own cold stores and robotics is not a core competency. Chemical compounds account for about 52.53% of samples handled, while biosamples are the fastest-growing sample type at close to a 17.75% CAGR.

Geography matters when you choose where to plant a bureau. North America holds about 38.23% of 2025 revenue thanks to its dense base of pharma and biotech headquarters, while Asia-Pacific is the fastest-growing region at around a 16.42% CAGR as Chinese and Indian CROs absorb outsourced screening work. In the United Kingdom the demand clusters around the Cambridge (Babraham), Oxford, Stevenage and Alderley Park life-science campuses, where small biotech spin-outs rarely have the capital to build automation in-house and are natural early customers for a local service bureau.

Most market reports stop at these segment shares. The number that actually decides whether your bureau survives is turnaround time: pharma screening teams will pay a premium and sign multi-year contracts for a partner who guarantees an assay-ready plate within a stated service-level window, and they will churn instantly from one who lets DMSO stock degrade through repeated freeze-thaw cycles. Your business plan should make that promise measurable.

What Pharma Buyers Ask First

These are the questions that come up in real procurement conversations with screening and discovery teams. Answer them inside the plan and you pre-empt most objections.

What It Costs to Open the Doors

A lean outsourced compound management bureau typically needs $180,000 to $950,000 (about £145,000 to £760,000) to reach operational readiness with paying clients. The wide band reflects one decision: how much automation you buy on day one. A full enterprise-scale automated store can cost between $1 million and $10 million alone (MarketsandMarkets), which is why almost every successful new entrant starts mid-capacity and adds modules once anchor clients are signed.

Cost Breakdown

• Automated cold/cryo store + one liquid handler: $90K–$520K (£72K–£416K) - the single largest line; buy mid-capacity, expand later
• Compound-management software / LIMS: $25K–$120K (£20K–£96K) - Titian Mosaic, Tecan or an integrated LIMS with Part 11 audit trails
• Lab fit-out, HVAC, -20°C/-80°C freezers, N₂ lines: $30K–$140K (£24K–£112K)
• Quality accreditation & validation (21 CFR Part 11, GLP): $15K–$60K (£12K–£48K) - the cost that gatekeeps every regulated client
• Consumables (DMSO, plates, tubes, barcodes): $8K–$45K (£6K–£36K)
• Working capital + scientific hires (3 months): $12K–$65K (£11K–£52K)

Notice where the money goes. Unlike a retail or food business, the dominant cost is capital equipment plus the validation work that makes that equipment trustworthy to a regulated buyer. A common and expensive mistake is to spend the whole budget on a flagship automated store before a single client has committed, leaving nothing for the validation and software that actually convert that hardware into billable, compliant capacity.

Funding & SBA Data

Because a compound management bureau is equipment-heavy, lenders treat it more like a specialist laboratory than a software startup. That works in your favour: the automated stores, freezers and liquid handlers are tangible, depreciable assets that can secure asset finance and SBA-backed lending.

In the United States, the SBA 7(a) loan funds up to $5 million with terms up to 25 years for real estate and up to 10 years for equipment, and is the most common route for a lab-services business with this capital profile. The SBA 504 programme is often a better fit for the largest fixed-asset purchases (automated stores, cold-room build-out), pairing a bank loan with a Certified Development Company debenture at a fixed rate. Life-science businesses sit under NAICS 541714 (research and development in biotechnology) or 541380 (testing laboratories); lenders use that code to benchmark approval. Expect a lender to require a full 5-year financial forecast, two to three signed or letter-of-intent client commitments, and evidence that your validation roadmap is funded.

In the United Kingdom, the government-backed Start Up Loan offers up to £25,000 per founder at 6% fixed interest with free mentoring - useful for early working capital but far below the equipment bill, so most UK founders combine it with asset finance (hire-purchase on the store and freezers) and, where the science is novel, SEIS/EIS equity from angel investors, which gives investors 50% (SEIS) or 30% (EIS) income-tax relief. Innovate UK grants and the life-science investment funds clustered around Cambridge and Stevenage are realistic non-dilutive top-ups for a bureau with a credible plan.

How a Bureau Makes Money

Revenue in compound management is a stack, not a single line. The base layer is recurring storage, priced per tube or per well per year, typically in the range of $0.10–$0.50 per tube annually depending on temperature class and access frequency. On top of that sits the higher-margin activity: reformatting and cherry-picking (pulling specific compounds into a custom plate) at roughly $40–$200 per plate, assay-ready plate production via acoustic dispensing, and project or FTE-based services where the client effectively rents your scientists and robots.

Worked Example

A bureau storing 1.2 million tubes at $0.28 per tube per year earns $336,000 in recurring storage revenue - predictable, contracted, and the bedrock of the valuation. Layer on 6,000 cherry-pick and assay-ready plates a year at an $85 blended fee and you add $510,000, for total annual revenue of roughly $846,000. After scientific labour (40–50% of revenue), depreciation on the automation, consumables and compliance overhead, net margin lands in the low-to-mid 20s. The strategic point: storage buys you the relationship and the recurring base; the plating and project work is where the margin lives.

Margins for a mature, well-utilised bureau typically run 18–32%. The biggest lever is store utilisation - empty capacity still costs you in power, monitoring and depreciation, so a plan that wins enough anchor clients to keep the store above 70% utilised is worth far more than one chasing the largest possible day-one footprint.

A Second Scenario: the Reformatting-Led Bureau

Not every founder wants to carry the capital of a large store. A reformatting-led bureau buys a smaller store and leans on plating volume. Picture 400,000 tubes stored at $0.30 per tube per year ($120,000 recurring) plus 9,000 assay-ready and cherry-pick plates at a $110 blended fee ($990,000). Total revenue lands near $1.11 million, with a higher proportion coming from value-added services where margins are strongest. The trade-off is that plating revenue is more variable than storage subscriptions, so the plan must show a pipeline deep enough to keep the dispensers busy month to month. This is why most lenders want to see both a recurring base and a services pipeline before they fund the equipment.

Whichever scenario you model, three numbers decide the outcome and belong on the first page of the financials: average revenue per stored tube, average revenue per plate produced, and store utilisation. Move any one of them and the whole forecast moves with it, which is exactly why a generic template that omits them fails to convince a specialist lender.

Three Business Models Compared

"Compound management business" is not one thing. There are three distinct models, each with a different capital profile, sales motion and risk. Most founders should pick one to lead with and treat the others as later expansions; trying to be all three at once is a classic way to under-resource each.

The competitive field for each model is real and named. On the equipment-and-storage side you are positioned against Azenta Life Sciences (which opened a 40,000-square-foot Billerica, Massachusetts sample-storage facility in 2023), Hamilton Company, Tecan (owner of Labcyte and the Echo acoustic dispenser), SPT Labtech and LiCONiC. On managed services you compete with bureaus such as Scotland's BioAscent, plus the compound-management arms of large CROs like WuXi AppTec, Pharmaron and Evotec, and library specialists such as Enamine. On software the incumbent is Titian Software, whose Mosaic platform (now operating as Cenevo) is the de facto standard for sample inventory and audit trails. A new entrant wins not by out-scaling these names but by out-serving a narrow client type - a faster local turnaround, a cleaner audit story, or a niche sample chemistry the giants treat as marginal.

Operations & the Sample Workflow

The operations section is where a compound management plan either earns trust or loses it. Investors and clients want to see that you understand the full sample journey, not just the room full of robots. The standard workflow runs through aggregation, registration, weighing, dissolution, storage, cherry-picking, plating and distribution, with quality control and an audit trail layered across every step. Each handoff is a place where identity, concentration or provenance can be lost, and the plan should describe the controls that prevent it.

A typical inbound flow looks like this. Material arrives from the client or a supplier such as Enamine and is registered against a unique barcode in the LIMS. Dry powder is weighed and dissolved into DMSO stock at a defined concentration, then tubes or plates are barcoded and placed into the automated store under the correct temperature class. When a screening team requests compounds, the system generates a cherry-pick list, the store retrieves the source tubes, a liquid handler or acoustic dispenser builds the assay-ready plate, and the finished plate is QC-checked and shipped or collected, with every action time-stamped in the audit trail.

The Equipment and Software Stack

A credible plan names the stack. On the storage side, that means an automated cold store from a vendor such as Azenta, Hamilton or LiCONiC, paired with -20°C and -80°C mechanical freezers and, for biosamples, liquid-nitrogen vapour storage. On the liquid-handling side, tip-based handlers from Tecan or Hamilton cover bulk transfers, while an acoustic dispenser (the Labcyte Echo, now part of Tecan) handles nanolitre transfers down to 2.5 nanolitres and enables miniaturisation into 1536-well plates, which saves expensive compound and supports high-throughput screening. Titian's Mosaic ties the whole chain together, recording each liquid handler's settings and specifying the correct one when switching between DMSO-based compounds and aqueous biologicals so that sample integrity is preserved across formulations.

The operational metric that matters most is store utilisation against turnaround time. A bureau that fills its store but cannot hit its service-level agreement will lose clients as fast as one that hits its SLA but runs the store half-empty. Build the plan around a staffing model that scales scientific headcount with plate volume, and show the month at which a second shift or a second liquid handler becomes necessary. Lenders read this as evidence you can grow without the wheels coming off.

• Aggregation & registration: intake, barcode, and LIMS entry with chain-of-custody from the first touch
• Weighing & dissolution: accurate DMSO stock preparation at defined concentrations
• Storage: temperature-class routing, inert/low-humidity atmosphere, continuous monitoring
• Cherry-picking & plating: automated retrieval and acoustic or tip-based plate production
• QC & distribution: identity/concentration checks, audit trail close-out, and SLA-tracked dispatch

Winning Your First Clients

A compound management bureau is a relationship and trust business, not a transactional one. Clients hand over assets that took years and millions to assemble, so they buy slowly and stay for years once they trust you. That dynamic shapes the entire go-to-market plan: the goal is not a high volume of small orders, it is a small number of anchor clients on multi-year contracts, each of whom validates the next.

The strongest early channel is proximity to a biotech cluster. Small spin-outs around Cambridge, Oxford, Stevenage, Boston/Cambridge MA, San Diego and the Bay Area rarely have the capital to build their own automation and are natural first customers for a local bureau that can offer a same-week turnaround and an in-person facility tour. A second channel is the referral network of contract research organisations and academic technology-transfer offices, who frequently need overflow storage or specialist plating they do not want to build internally. A third is direct outreach to discovery and screening leads with a concrete promise: a published SLA, a 21 CFR Part 11 validation roadmap, and a transparent per-tube and per-plate price list.

Positioning should lead with the metrics buyers actually evaluate. Most competitors talk about capacity and equipment; the bureau that wins talks about turnaround time, freeze-thaw discipline, audit-trail completeness, and the named accreditations it holds. Your business plan should translate that positioning into a costed sales funnel: how many facility tours convert to letters of intent, how many letters of intent convert to signed contracts, and what the average contract value and tenure are. That funnel is what an investor uses to believe your revenue ramp, and it is exactly what separated the funded plans we have written from the ones that stalled.

Quality, Compliance & Licensing

In compound management, compliance is not paperwork bolted on at the end - it is the product. A library a client spent years and millions assembling is only worth storing with a partner who can prove the chain of custody and the environmental record. Plan and budget for the following from day one.

United States

• FDA 21 CFR Part 11 - electronic records and signatures; validated audit trails are mandatory for any GxP client (validation typically $15K–$60K, 3–6 months)
• Good Laboratory Practice (21 CFR Part 58) - including continuous temperature monitoring with deviation alerts at roughly ±2°C
• DEA registration - required only if you handle controlled-substance compounds (about $888 per schedule every 3 years)
• State biohazard/lab permits and OSHA compliance for cryogenic and chemical handling

United Kingdom

• Human Tissue Authority (HTA) licence - required if you store human biosamples or tissue (around £5,000+ annually, 8–12 weeks to obtain)
• MHRA GLP / GCLP compliance monitoring for regulated study material
• Home Office controlled-drug licence if handling scheduled substances (£3,655+, 8–16 weeks)
• UKAS / ISO accreditation increasingly expected by pharma clients as a procurement gate

European Union & Asia-Pacific

• EU Annex 11 - computerised-systems rules requiring continuous environmental monitoring and electronic audit trails for GMP-adjacent storage
• ISO 20387 biobank accreditation - increasingly requested when pharma outsources biosample storage to APAC hubs
• Singapore HSA biobanking governance and equivalent national frameworks as you expand into the fastest-growing region

Five Costly Mistakes to Avoid

We have reviewed enough life-science plans to see the same avoidable errors sink otherwise good bureaus. Address each one explicitly and your plan reads as written by an operator, not an outsider.

1. Selling "storage" instead of integrity. Pharma buyers do not pay a premium for shelf space; they pay for verified sample integrity, chain-of-custody, and a turnaround guarantee. A plan that frames the offer as cheap storage competes on price and loses. Frame it as a managed-integrity service with a measurable SLA.
2. Under-budgeting validation. The 21 CFR Part 11 and GLP work that makes your audit trail trustworthy can take three to six months and cost $15K to $60K. Founders who treat it as an afterthought find that no regulated client will sign until it is done, stranding an expensive store with no revenue against it.
3. Ignoring DMSO freeze-thaw degradation. Every uncontrolled freeze-thaw cycle and every hour of humidity exposure degrades DMSO stock. A bureau that does not specify liquid-class handling and cycle limits will quietly destroy sample quality and lose the client the first time a screen produces noise.
4. Buying a flagship store before signing clients. A $1M-plus enterprise automated store looks impressive and bankrupts founders who buy it on speculation. Start with mid-capacity automation sized to your first one or two anchor clients, and expand modularly once contracted demand justifies it.
5. Modelling revenue on storage alone. Per-tube storage is the recurring base, but the margin lives in reformatting, cherry-picking and assay-ready plate production. A forecast built only on storage understates revenue and hides the real economics from investors.

Compound Management Glossary

Investors and lenders will not all be scientists. A short glossary in your plan signals command of the domain and removes friction in due diligence.

Cherry-picking

Selecting and retrieving specific compounds from a large stored library to build a custom plate for a particular assay.

Assay-ready plate (ARP)

A microplate pre-loaded with compounds at the concentrations a screening team needs, ready to use without further dilution.

Acoustic dispensing

Contactless transfer of nanolitre volumes using sound energy (e.g. the Labcyte/Tecan Echo), able to move as little as 2.5 nanolitres and enabling miniaturisation into 1536-well plates.

DMSO

Dimethyl sulfoxide, the solvent most compounds are dissolved in. It is hygroscopic, so uncontrolled humidity and repeated freeze-thaw cycles degrade stock quality.

Freeze-thaw cycle

Each time a sample is warmed and refrozen for access. Minimising cycles is central to preserving sample integrity and a key selling point of a good bureau.

LIMS

Laboratory Information Management System - software that tracks sample location, history and audit trail; Titian's Mosaic is the category standard for compound management.

Cryogenic storage

Storage at or below -150°C, usually in liquid-nitrogen vapour phase, used for biosamples and cell-based material.

Sample Business Plan Preview

Here is an extract from a compound management plan written by our team, so you can see the level of specificity that wins funding:

What's Inside the Template

Every Avvale business plan template is pre-structured for your industry. The compound management edition includes:

• Executive Summary - your bureau, its model and its funding ask, written to hold an investor's attention in 60 seconds
• Company Overview - legal structure, founder operating background, facility location relative to a biotech cluster
• Industry Analysis - market size, the products-vs-services split, and regional demand with citations
• Customer Analysis - pharma, biotech and CRO buyer segments, their procurement triggers and decision criteria
• Competitor Analysis - mapping against Azenta, Tecan, BioAscent and the relevant named players in your model
• Service & Operations Plan - storage classes, reformatting workflow, SLAs, and the automation and software stack
• Compliance Plan - 21 CFR Part 11, GLP and HTA roadmap, the section that de-risks the equipment spend for a lender
• Management Team - scientific and operational bios, advisory board, and the key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, store-utilisation sensitivity, break-even analysis, and startup capital requirements - exactly what an SBA lender or asset-finance provider expects to see.

If you are researching adjacent niches, our business plan writer team also maintains plans for the biotech drug discovery, drug discovery and analytical laboratory sectors, all of which share the same regulated, equipment-heavy DNA as compound management. Browse the full library of free business plan templates to compare structures.

Frequently Asked Questions